

## Utilization Management and Clinical Medical Policy

|  |   |  |  |                                       |
|--|---|--|--|---------------------------------------|
| <b>Policy Name:</b><br>Daratumumab (Darzalex®) and daratumumab and hyaluronidase-fihj (Darzalex Faspro®) | <b>Policy Number:</b><br>MP-RX-FP-21-23 | <b>Scope:</b><br><input checked="" type="checkbox"/> MMM MA<br><input checked="" type="checkbox"/> MMM MultiHealth | <b>Origination Date:</b><br>11/30/2023 | <b>Effective Date:</b><br>03/24/2026  |
|  |   |  | <b>Last Review Date:</b><br>03/24/2026 | <b>Frequently Revision:</b><br>Annual |

### Service Category:

- |  |   |
|--|---|
| <input type="checkbox"/> Anesthesia                          | <input type="checkbox"/> Medicine Services and Procedures   |
| <input type="checkbox"/> Surgery                             | <input type="checkbox"/> Evaluation and Management Services |
| <input type="checkbox"/> Radiology Procedures                | <input type="checkbox"/> DME/Prosthetics or Supplies        |
| <input type="checkbox"/> Pathology and Laboratory Procedures | <input checked="" type="checkbox"/> Other: Part B Drugs     |

### Service Description:

This document addresses the use of daratumumab-containing products approved by the Food and Drug Administration (FDA) for the treatment of certain patients with newly diagnosed and relapsed/refractory multiple myeloma (MM), high-risk smoldering multiple myeloma, and light chain (AL) amyloidosis.

### Background Information:

Daratumumab is a human anti-CD38 monoclonal antibody. Darzalex is administered intravenously, with weight based dosing, over hours. Darzalex Faspro is a subcutaneous dosage form that allows for flat dosing and is administered over 3-5 minutes. (Darzalex Faspro contains hyaluronidase-fihj to facilitate subcutaneous delivery.) The National Comprehensive Cancer Network® (NCCN) provides category 2A recommendations for the use of daratumumab. Approved and recommended uses are listed below:

#### Newly diagnosed multiple myeloma:

- *Ineligible for stem cell transplant:*
  - In combination with bortezomib, melphalan, and prednisone (Label)
  - In combination with lenalidomide and dexamethasone (Label)
  - In combination with cyclophosphamide, bortezomib, and dexamethasone (NCCN 2A)
  - In combination with carfilzomib, lenalidomide, and dexamethasone (DP BIIa)
  - In combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) (Darzalex Faspro only; Label)
- *Eligible for stem cell transplant:*
  - In combination with bortezomib, thalidomide, and dexamethasone (Label)
  - In combination with bortezomib, lenalidomide, and dexamethasone (NCCN 2A)
  - In combination with cyclophosphamide, bortezomib, and dexamethasone (NCCN 2A)
  - In combination with carfilzomib, lenalidomide, and dexamethasone (NCCN 2A)

#### Relapsed or refractory multiple myeloma:

- In combination with lenalidomide and dexamethasone (Label)
- In combination with bortezomib and dexamethasone (Label)
- In combination with pomalidomide and dexamethasone in those who have received at least 2 prior therapies (or 1 prior line of therapy) including lenalidomide and a proteasome inhibitor (Label, NCCN 2A)
- As a single agent in those who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent (Label)

## Utilization Management and Clinical Medical Policy

|   |  |  |  |                                       |
|---|--|--|--|---------------------------------------|
| <b>Policy Name:</b><br><b>Daratumumab (Darzalex®) and daratumumab and hyaluronidase-fihj (Darzalex Faspro®)</b> | <b>Policy Number:</b><br><b>MP-RX-FP-21-23</b> | <b>Scope:</b><br><input checked="" type="checkbox"/> MMM MA<br><input checked="" type="checkbox"/> MMM MultiHealth | <b>Origination Date:</b><br>11/30/2023 | <b>Effective Date:</b><br>03/24/2026  |
|   |  |  | <b>Last Review Date:</b><br>03/24/2026 | <b>Frequently Revision:</b><br>Annual |

- In combination with carfilzomib and dexamethasone (Label)
- In combination with cyclophosphamide, bortezomib, and dexamethasone (NCCN 2A)
- In combination with selinexor and dexamethasone (NCCN 2A)
- In combination with venetoclax and dexamethasone for patients with t(11;14) (NCCN 2A)

### Maintenance therapy for multiple myeloma:

- As a single agent for transplant candidates after response to primary myeloma therapy (NCCN 2A) or for response or stable disease following transplant (NCCN 1)
- In combination with lenalidomide for transplant candidates (high risk disease only) after response to primary myeloma therapy (NCCN 2A) or for response or stable disease following transplant (NCCN 1)

### High-risk smoldering multiple myeloma (HR-SMM):

- Darzalex Faspro as monotherapy (Label)

### Systemic light chain amyloidosis:

- Darzalex Faspro in combination with bortezomib, cyclophosphamide, and dexamethasone (Label)
- As a single agent (NCCN 2A)
- In combination with lenalidomide and dexamethasone (NCCN 2A)
- In combination with venetoclax for t(11;14) (NCCN 2A)
- Dexamethasone with or without bortezomib (DP B IIa)

Emerging data from prospective and retrospective studies indicate daratumumab-containing regimens produce clinically meaningful responses in patients with systemic light chain amyloidosis. Most recently, the FDA has approved Darzalex Faspro for the treatment of light chain amyloidosis in combination with bortezomib, cyclophosphamide, and dexamethasone (VCd). This indication is under accelerated approval and continued approval may be contingent upon confirmatory trials. It is not indicated and not recommended for treatment of light chain amyloidosis in individuals who have NYHA class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials. There is also evidence to support Darzalex as a single agent or in combination with dexamethasone with or without bortezomib in relapsed or refractory systemic light chain amyloidosis (Kimmich 2020, Roussel 2020).

### Definitions and Measures

- Line of Therapy:
  - First-line therapy: The first or primary treatment for the diagnosis, which may include surgery, chemotherapy, radiation therapy or a combination of these therapies.
  - Second-line therapy: Treatment given when initial treatment (first-line therapy) is not effective or there is disease progression.
  - Third-line therapy: Treatment given when both initial (first-line therapy) and subsequent treatment (second-line therapy) are not effective or there is disease progression.
- Multiple myeloma: A type of cancer that begins in plasma cells (white blood cells that produce antibodies).

## Utilization Management and Clinical Medical Policy

|  |   |  |  |                                       |
|--|---|--|--|---------------------------------------|
| <b>Policy Name:</b><br>Daratumumab (Darzalex®) and daratumumab and hyaluronidase-fihj (Darzalex Faspro®) | <b>Policy Number:</b><br>MP-RX-FP-21-23 | <b>Scope:</b><br><input checked="" type="checkbox"/> MMM MA<br><input checked="" type="checkbox"/> MMM MultiHealth | <b>Origination Date:</b><br>11/30/2023 | <b>Effective Date:</b><br>03/24/2026  |
|  |   |  | <b>Last Review Date:</b><br>03/24/2026 | <b>Frequently Revision:</b><br>Annual |

- Plasma cell leukemia: A rare and aggressive form of multiple myeloma characterized by high levels of plasma cells in the peripheral blood.
- Proteasome inhibitors: A class of drugs used to treat multiple myeloma that work by blocking the action of proteasomes which are cellular complexes that break down proteins. Examples include bortezomib, carfilzomib and ixazomib.
- Refractory Disease: Illness or disease that does not respond to treatment.
- Relapse or recurrence: After a period of improvement, during which time a disease (for example, cancer) could not be detected, the return of signs and symptoms of illness or disease. For cancer, it may come back to the same place as the original (primary) tumor or to another place in the body.

### Approved Indications

- See Background section above.

### Other Uses

- The National Comprehensive Cancer Network® (NCCN) provides a category 2A recommendation for the use of daratumumab in combination with venetoclax and dexamethasone for patients with t(11;14) as useful in certain circumstances for previously treated multiple myeloma. Guidelines have not been updated with literature and discussion support for this recommendation to date.

## Utilization Management and Clinical Medical Policy

|  |   |  |  |                                       |
|--|---|--|--|---------------------------------------|
| <b>Policy Name:</b><br>Daratumumab (Darzalex®) and daratumumab and hyaluronidase-fihj (Darzalex Faspro®) | <b>Policy Number:</b><br>MP-RX-FP-21-23 | <b>Scope:</b><br><input checked="" type="checkbox"/> MMM MA<br><input checked="" type="checkbox"/> MMM MultiHealth | <b>Origination Date:</b><br>11/30/2023 | <b>Effective Date:</b><br>03/24/2026  |
|  |   |  | <b>Last Review Date:</b><br>03/24/2026 | <b>Frequently Revision:</b><br>Annual |

### Medical Necessity Guidelines:

When a drug is being reviewed for coverage under a member’s medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

*Darzalex® (Daratumumab) and Darzalex Faspro® (Daratumumab and hyaluronidase-fihj)*

- A. Criteria For Initial Approval** (*Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient’s diagnosis for the drug and confirming that the patient has met **all** approval criteria.*)
- i. Individual has a diagnosis of multiple myeloma, including plasma cell leukemia; **AND**
  - ii. Individual is using for one of the following:
    - A. Newly diagnosed multiple myeloma for those who are ineligible for stem cell transplantation:
      - 1. In combination with melphalan, prednisone and a proteasome inhibitor (PI) (for example, bortezomib); **OR**
      - 2. In combination with lenalidomide and dexamethasone; **OR**
      - 3. In combination with bortezomib, lenalidomide, and dexamethasone (VRd) (Darzalex Faspro only; Label);
    - OR**
    - B. Newly diagnosed multiple myeloma for those who are eligible for stem cell transplant:
      - 1. In combination with bortezomib, dexamethasone, and either thalidomide or lenalidomide (Label); **OR**
      - 2. In combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation (Darzalex Faspro only; Label);
    - OR**
    - C. Newly diagnosed multiple myeloma in combination with carfilzomib, lenalidomide, and dexamethasone;
    - OR**
    - D. Newly diagnosed multiple myeloma in combination with cyclophosphamide, bortezomib, and dexamethasone;
    - OR**
    - E. Relapsed or refractory multiple myeloma (Label, NCCN 2A):
      - 1. As a single agent following therapy with at least two prior lines of therapy including a PI (for example, bortezomib, carfilzomib, or ixazomib) and an immunomodulatory agent (for example, thalidomide, lenalidomide, or pomalidomide); **OR**
      - 2. In combination with cyclophosphamide, bortezomib, and dexamethasone; **OR**

## Utilization Management and Clinical Medical Policy

|  |   |  |  |                                       |
|--|---|--|--|---------------------------------------|
| <b>Policy Name:</b><br>Daratumumab (Darzalex®) and daratumumab and hyaluronidase-fihj (Darzalex Faspro®) | <b>Policy Number:</b><br>MP-RX-FP-21-23 | <b>Scope:</b><br><input checked="" type="checkbox"/> MMM MA<br><input checked="" type="checkbox"/> MMM MultiHealth | <b>Origination Date:</b><br>11/30/2023 | <b>Effective Date:</b><br>03/24/2026  |
|  |   |  | <b>Last Review Date:</b><br>03/24/2026 | <b>Frequently Revision:</b><br>Annual |

- 3. In combination with selinexor and dexamethasone; **OR**
  - 4. In combination with venetoclax and dexamethasone for patients with t(11:14); **OR**
  - 5. As combination therapy following treatment with at least one prior line of therapy when used with one of following:
    - a. A PI (for example, bortezomib, carfilzomib, or ixazomib) and dexamethasone; **OR**
    - b. An immunomodulatory agent (for example, thalidomide, lenalidomide, or pomalidomide) and dexamethasone;
- OR**
- F. As single-agent maintenance therapy for multiple myeloma in transplant candidates (NCCN 2A); **OR**
  - G. In combination with lenalidomide for maintenance therapy of high-risk multiple myeloma in transplant candidates (NCCN 2A);
  - H. High risk smoldering multiple myeloma (NCCN 1, Label) (Darzalex Faspro only; Label);
- OR**
- iii. Individual has a diagnosis of systemic light chain amyloidosis; **AND**
    - A. Individual is using as a single agent (NCCN 2A);
- OR**
- B. Individual is using in combination:
    - 1. Bortezomib, cyclophosphamide, and dexamethasone (Darzalex Faspro only; Label); **OR**
    - 2. Lenalidomide and dexamethasone (NCCN 2A); **OR**
    - 3. Venetoclax for t(11;14) (NCCN 2A); **OR**
    - 4. Dexamethasone with or without bortezomib (DP B IIa)
- OR**
- iv. Individual has a diagnosis of pediatric Acute Lymphoblastic Leukemia (ALL), as T-ALL (NCCN 2A); **AND**
  - v. Individual is using a daratumumab-containing regimen (e.g. daratumumab, vincristine, pegaspargase or calaspargase, doxorubicin, and prednisone or dexamethasone) for relapsed/refractory T-ALL.
- OR**
- vi. Individual has a diagnosis of POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome (NCCN 2A).
- B. Criteria For Continuation of Therapy**

## Utilization Management and Clinical Medical Policy

|   |  |  |  |                                       |
|---|--|--|--|---------------------------------------|
| <b>Policy Name:</b><br><b>Daratumumab (Darzalex®) and daratumumab and hyaluronidase-fihj (Darzalex Faspro®)</b> | <b>Policy Number:</b><br><b>MP-RX-FP-21-23</b> | <b>Scope:</b><br><input checked="" type="checkbox"/> MMM MA<br><input checked="" type="checkbox"/> MMM MultiHealth | <b>Origination Date:</b><br>11/30/2023 | <b>Effective Date:</b><br>03/24/2026  |
|   |  |  | <b>Last Review Date:</b><br>03/24/2026 | <b>Frequently Revision:</b><br>Annual |

- i. MMM considers continuation of daratumumab (Darzalex®) and daratumumab and hyaluronidase-fihj (Darzalex Faspro®) therapy medically necessary in members requesting reauthorization for an indication listed in Section A above (Criteria for Initial Approval) when there is no evidence of unacceptable toxicity or disease progression while on the current regimen, and the recommended duration of therapy has not been exceeded. The following information should be submitted for reauthorization:
  - A. A current oncology note documenting the patient’s response to treatment showing no progression of disease.
  - B. Current imaging studies and other objective measures (e.g., M-protein/serum or urine electrophoresis, serum free light chains, bone marrow evaluation), as appropriate, showing no progression of disease when compared with previous results.
- ii. Maximum duration of therapy:
  - A. For the indication of light chain amyloidosis: Up to a maximum of 2 years.
  - B. For patients with newly diagnosed multiple myeloma eligible for ASCT (in combination with Bortezomib, Thalidomide and Dexamethasone): Up to a total of 16 doses.
  - C. For patients with newly diagnosed multiple myeloma eligible for ASCT (in combination with bortezomib, lenalidomide and dexamethasone [VRd]) (Darzalex Faspro only): Up to a total of 16 doses.
  - D. For the indication of high-risk smoldering multiple myeloma (Darzalex Faspro only): Until diagnosis of multiple myeloma or a maximum of 3 years.
  - E. For all other indications: until unacceptable toxicity or disease progression

### C. Authorization Duration

- i. Initial Approval Duration: Up to 6 months
- ii. Reauthorization Approval Duration: Up to 6 months

### D. Conditions Not Covered

*Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):*

- i. Requests for Darzalex (daratumumab) or Darzalex Faspro (daratumumab and hyaluronidase-fihj) may not be approved if the above criteria (Section A: Criteria for Initial Approval) are not met and for all other indications not included above.

## Utilization Management and Clinical Medical Policy

|   |   |   |  |                                       |
|---|---|---|--|---------------------------------------|
| <b>Policy Name:</b><br>Daratumumab (Darzalex®)<br>and daratumumab and<br>hyaluronidase-fihj (Darzalex<br>Faspro®) | <b>Policy Number:</b><br>MP-RX-FP-21-23 | <b>Scope:</b><br><input checked="" type="checkbox"/> MMM MA<br><input checked="" type="checkbox"/> MMM<br>MultiHealth | <b>Origination Date:</b><br>11/30/2023 | <b>Effective Date:</b><br>03/24/2026  |
|   |   |   | <b>Last Review Date:</b><br>03/24/2026 | <b>Frequently Revision:</b><br>Annual |

## Utilization Management and Clinical Medical Policy

|   |  |  |  |                                       |
|---|--|--|--|---------------------------------------|
| <b>Policy Name:</b><br><b>Daratumumab (Darzalex®) and daratumumab and hyaluronidase-fihj (Darzalex Faspro®)</b> | <b>Policy Number:</b><br><b>MP-RX-FP-21-23</b> | <b>Scope:</b><br><input checked="" type="checkbox"/> MMM MA<br><input checked="" type="checkbox"/> MMM MultiHealth | <b>Origination Date:</b><br>11/30/2023 | <b>Effective Date:</b><br>03/24/2026  |
|   |  |  | <b>Last Review Date:</b><br>03/24/2026 | <b>Frequently Revision:</b><br>Annual |

### Limits or Restrictions:

#### A. Therapeutic Alternatives

The list below includes preferred alternative therapies recommended in the approval criteria and may be subject to prior authorization.

- i. N/A

#### B. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

For daratumumab and hyaluronidase-fihj (Darzalex Faspro):

| Use  | Dosing Schedule  | Recommended dose  | Duration of Therapy                                |
|--|--|---|--|
| <b>Multiple Myeloma</b>  |  |   |  |
| <i>Combination Therapy</i>   |  |   |  |
| In combination with lenalidomide and dexamethasone (Darzalex FASPRO-Rd)              | <ul style="list-style-type: none"> <li>• Weeks 1 to 8: Administer weekly (total of 8 doses)</li> <li>• Weeks 9 to 24: Administer every two weeks (total of 8 doses)</li> <li>• Week 25 onwards until disease progression: every 4 weeks</li> </ul> | 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) administered subcutaneously | Until disease progression or unacceptable toxicity |
| In combination with pomalidomide and dexamethasone (Darzalex Faspro-Pd)              |  |   |  |
| In combination with carfilzomib and dexamethasone (Darzalex Faspro-Kd)               |  |   |  |
| In Combination with Bortezomib, Melphalan and Prednisone (Darzalex Faspro-VMP)       | <ul style="list-style-type: none"> <li>• Weeks 1 to 6: weekly (total of 6 doses).</li> <li>• Weeks 7 to 54: every three weeks (total of 16 doses).</li> <li>• Week 55 onwards until disease progression: every 4 weeks</li> </ul>                  |   |  |
| In Combination with Bortezomib, Thalidomide, and Dexamethasone (Darzalex Faspro-VTd) | <ul style="list-style-type: none"> <li>• Weeks 1 to 8: Administer weekly (total of 8 doses)</li> <li>• Weeks 9 to 16: Every two weeks (total of 4 doses)</li> </ul>  | 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase)                             | A total of 16 doses                                |

## Utilization Management and Clinical Medical Policy

|   |  |  |  |                                       |
|---|--|--|--|---------------------------------------|
| <b>Policy Name:</b><br><b>Daratumumab (Darzalex®) and daratumumab and hyaluronidase-fihj (Darzalex Faspro®)</b> | <b>Policy Number:</b><br><b>MP-RX-FP-21-23</b> | <b>Scope:</b><br><input checked="" type="checkbox"/> MMM MA<br><input checked="" type="checkbox"/> MMM MultiHealth | <b>Origination Date:</b><br>11/30/2023 | <b>Effective Date:</b><br>03/24/2026  |
|   |  |  | <b>Last Review Date:</b><br>03/24/2026 | <b>Frequently Revision:</b><br>Annual |

|   |   |   |  |
|---|---|---|--|
|   | <b>Stop for high dose chemotherapy and ASCT</b> <ul style="list-style-type: none"> <li>Consolidation (post-ASCT): weeks 1 to 8: Every two weeks (total of 4 doses)</li> </ul>   | administered subcutaneously   |  |
| In Combination with Bortezomib, Lenalidomide, and Dexamethasone (Darzalex Faspro-VRd)                                       | <ul style="list-style-type: none"> <li>Weeks 1 to 8: Administer weekly (total of 8 doses)</li> <li>Weeks 9 to 16: Every two weeks (total of 4 doses)</li> </ul> <b>Stop for high dose chemotherapy and ASCT</b> <ul style="list-style-type: none"> <li>Consolidation: weeks 1 to 8: Every two weeks (total of 4 doses)</li> </ul> | 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) administered subcutaneously | A total of 16 doses                                |
| In Combination with Bortezomib and Dexamethasone (Darzalex Faspro-Vd)   | <ul style="list-style-type: none"> <li>Weeks 1 to 9: weekly (total of 9 doses).</li> <li>Weeks 10 to 24: every three weeks (total of 5 doses).</li> <li>Week 25 onwards until disease progression: every 4 weeks</li> </ul>   | 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) administered subcutaneously | Until disease progression or unacceptable toxicity |
| In combination with bortezomib, lenalidomide, and dexamethasone (DARZALEX FASPRO-VRd) <i>ASCT ineligible</i> (3-week cycle) | <ul style="list-style-type: none"> <li>Weeks 1–6: weekly (total of 6 doses)</li> <li>Weeks 7–24: every 3 weeks (total of 6 doses; first q3w dose at Week 7)</li> <li>Week 25 onwards: every 4 weeks</li> </ul>  | 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) administered subcutaneously | Until disease progression or unacceptable toxicity |
| High-risk smoldering multiple myeloma <i>Monotherapy</i> (4-week cycle)   | <ul style="list-style-type: none"> <li>Weeks 1–8: weekly (total of 8 doses)</li> <li>Weeks 9–24: every 2 weeks (total of 8 doses)</li> <li>Week 25 onwards until diagnosis of MM: every 4 weeks</li> </ul>  | 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) administered subcutaneously | Until diagnosis of MM or a maximum of 3 years      |
| <b>Light Chain Amyloidosis</b>  |   |   |  |
| In Combination with Bortezomib, Cyclophosphamide and Dexamethasone (Darzalex Faspro-VCd)                                    | <ul style="list-style-type: none"> <li>Weeks 1 to 8: Administer weekly (total of 8 doses)</li> <li>Weeks 9 to 24: Administer every two weeks (total of 8 doses)</li> <li>Week 25 onwards: every 4 weeks</li> </ul>  | 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase)                             | Up to a maximum of 2 years                         |

## Utilization Management and Clinical Medical Policy

|  |   |  |  |                                       |
|--|---|--|--|---------------------------------------|
| <b>Policy Name:</b><br>Daratumumab (Darzalex®) and daratumumab and hyaluronidase-fihj (Darzalex Faspro®) | <b>Policy Number:</b><br>MP-RX-FP-21-23 | <b>Scope:</b><br><input checked="" type="checkbox"/> MMM MA<br><input checked="" type="checkbox"/> MMM MultiHealth | <b>Origination Date:</b><br>11/30/2023 | <b>Effective Date:</b><br>03/24/2026  |
|  |   |  | <b>Last Review Date:</b><br>03/24/2026 | <b>Frequently Revision:</b><br>Annual |

|  |  |                             |  |
|--|--|-----------------------------|--|
|  |  | administered subcutaneously |  |
|--|--|-----------------------------|--|

*For daratumumab (Darzalex):*

| Use   | Dosing Schedule   | Recommended Dose  | Duration of Therapy                                |
|---|---|---|--|
| <b>Multiple Myeloma</b>   |   |   |  |
| Monotherapy   | <ul style="list-style-type: none"> <li>Weeks 1 to 8: Administer weekly (total of 8 doses)</li> <li>Weeks 9 to 24: Administer every two weeks (total of 8 doses)</li> <li>Week 25 onwards until disease progression: every 4 weeks</li> </ul>  | 16 mg/kg actual body weight administered as an intravenous infusion | Until disease progression or unacceptable toxicity |
| In combination with lenalidomide and dexamethasone (D-Rd)             |   |   |  |
| In combination with pomalidomide and dexamethasone (D-Pd)             |   |   |  |
| In Combination with Bortezomib, Melphalan and Prednisone (D-VMP)      | <ul style="list-style-type: none"> <li>Weeks 1 to 6: Administer weekly (total of 6 doses)</li> <li>Weeks 7 to 54: Administer every three weeks (total of 16 doses)</li> <li>Week 55 onwards until disease progression: every 4 weeks</li> </ul>   | 16 mg/kg actual body weight administered as an intravenous infusion | Until disease progression or unacceptable toxicity |
| In Combination with Bortezomib, Thalidomide and Dexamethasone (D-VTd) | <ul style="list-style-type: none"> <li>Weeks 1 to 8: Administer weekly (total of 8 doses)</li> <li>Weeks 9 to 16: Administer every two weeks (total of 4 doses)</li> </ul> <p><b>Stop for high dose chemotherapy and ASCT</b></p> <ul style="list-style-type: none"> <li>Consolidation (post-ASCT): Week 1 to 8: Administer every two weeks (total of 4 doses)</li> </ul> | 16 mg/kg actual body weight administered as an intravenous infusion | A total of 16 doses                                |
| In Combination with Bortezomib and Dexamethasone (D-Vd)               | <ul style="list-style-type: none"> <li>Weeks 1 to 9: Administer weekly (total of 9 doses)</li> <li>Weeks 10 to 24: Administer every three weeks (total of 5 doses)</li> <li>Week 25 onwards until disease progression: every 4 weeks</li> </ul>   | 16 mg/kg actual body weight administered as an intravenous infusion | Until disease progression or unacceptable toxicity |

## Utilization Management and Clinical Medical Policy

|  |   |  |  |                                       |
|--|---|--|--|---------------------------------------|
| <b>Policy Name:</b><br>Daratumumab (Darzalex®) and daratumumab and hyaluronidase-fihj (Darzalex Faspro®) | <b>Policy Number:</b><br>MP-RX-FP-21-23 | <b>Scope:</b><br><input checked="" type="checkbox"/> MMM MA<br><input checked="" type="checkbox"/> MMM MultiHealth | <b>Origination Date:</b><br>11/30/2023 | <b>Effective Date:</b><br>03/24/2026  |
|  |   |  | <b>Last Review Date:</b><br>03/24/2026 | <b>Frequently Revision:</b><br>Annual |

|   |  |  |  |
|---|--|--|--|
| In Combination with Carfilzomib and Dexamethasone (DKd) | <ul style="list-style-type: none"> <li>• Week 1: Day 1 and Day 2 (split first dose)</li> <li>• Weeks 2 to 8: Administer weekly (total of 7 doses)</li> <li>• Weeks 9 to 24: Administer every two weeks (total of 8 doses)</li> <li>• Week 25 onwards until disease progression: every 4 weeks</li> </ul> | 16 mg/kg actual body weight IV infusion (first dose is split as 8 mg/kg on Day 1 and 8 mg/kg on Day 2) | Until disease progression or unacceptable toxicity |
| <b>Exceptions</b>                                       |  |  |  |
| None  |  |  |  |

## Utilization Management and Clinical Medical Policy

|  |   |  |  |                                       |
|--|---|--|--|---------------------------------------|
| <b>Policy Name:</b><br>Daratumumab (Darzalex®) and daratumumab and hyaluronidase-fihj (Darzalex Faspro®) | <b>Policy Number:</b><br>MP-RX-FP-21-23 | <b>Scope:</b><br><input checked="" type="checkbox"/> MMM MA<br><input checked="" type="checkbox"/> MMM MultiHealth | <b>Origination Date:</b><br>11/30/2023 | <b>Effective Date:</b><br>03/24/2026  |
|  |   |  | <b>Last Review Date:</b><br>03/24/2026 | <b>Frequently Revision:</b><br>Annual |

### Codes Information:

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

#### ICD-10 Diagnostic Codes:

| Codes         | Description  |
|---------------|--|
| C90.00-C90.32 | Multiple myeloma and malignant plasma cell neoplasms   |
| C91.00-C91.02 | Acute lymphoblastic leukemia   |
| D47.2         | Monoclonal gammopathy (code commonly used for POEMS syndrome)                                |
| T86.5         | Complications of stem cell transplant  |
| E85.3         | Secondary systemic amyloidosis   |
| E85.4         | Organ-limited amyloidosis  |
| E85.81        | Light chain (AL) amyloidosis   |
| E85.89        | Other amyloidosis  |
| E85.9         | Amyloidosis, unspecified   |
| Z51.11-Z51.12 | Encounter for antineoplastic chemotherapy and immunotherapy                                  |
| Z85.79        | Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues |
| Z94.84        | Stem cells transplant status   |

#### HCPCS Codes:

| Codes | Description  |
|-------|--|
| J9145 | Injection, daratumumab, 10 mg [DARZALEX]                               |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj [Darzalex Faspro] |

## Utilization Management and Clinical Medical Policy

|   |  |  |  |                                       |
|---|--|--|--|---------------------------------------|
| <b>Policy Name:</b><br><b>Daratumumab (Darzalex®) and daratumumab and hyaluronidase-fihj (Darzalex Faspro®)</b> | <b>Policy Number:</b><br><b>MP-RX-FP-21-23</b> | <b>Scope:</b><br><input checked="" type="checkbox"/> MMM MA<br><input checked="" type="checkbox"/> MMM MultiHealth | <b>Origination Date:</b><br>11/30/2023 | <b>Effective Date:</b><br>03/24/2026  |
|   |  |  | <b>Last Review Date:</b><br>03/24/2026 | <b>Frequently Revision:</b><br>Annual |

### Reference Information:

1. Chari A, Martinez-Lopez J, Mateos M, et al. Daratumumab in combination with carfilzomib and dexamethasone in lenalidomide- refractory patients with relapsed multiple myeloma: Subgroup analysis of MMY1001. *J Clin Oncol.* 2018; 36(15):8002-8002
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Jakubowiak A, Chari A, Lonial S, et al. Daratumumab in combination with carfilzomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (MMY1001). *J Clin Oncol.* 2017; 35(15):8000-8000.
5. Janssen Biotech, Inc.. (n.d.). *DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) prescribing information* [PDF]. Retrieved February 17, 2026, from <https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf>.
6. Janssen Biotech, Inc. (n.d.). *DARZALEX (daratumumab) prescribing information* [PDF]. Retrieved February 17, 2026, from <https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf>.
7. Kimmich CR, Terzer T, Benner A, et al: Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. *Blood* 2020; 135(18):1517-1530.
8. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2025; Updated periodically.
9. Roussel M, Merlini G, Chevret S, et al. A prospective phase II of daratumumab in previously treated systemic light chain amyloidosis (AL) patients. *Blood.* 2020; 135: 1531-1540.
10. NCCN Clinical Practice Guidelines in Oncology™. © 2023 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed January 2023.
  - a. Multiple Myeloma. V4.2026. Revised November 26, 2025.
  - b. Systemic Light Chain Amyloidosis. V1.2026. Revised June 11, 2025.

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

## Utilization Management and Clinical Medical Policy

|  |   |  |  |                                       |
|--|---|--|--|---------------------------------------|
| <b>Policy Name:</b><br>Daratumumab (Darzalex®) and daratumumab and hyaluronidase-fihj (Darzalex Faspro®) | <b>Policy Number:</b><br>MP-RX-FP-21-23 | <b>Scope:</b><br><input checked="" type="checkbox"/> MMM MA<br><input checked="" type="checkbox"/> MMM MultiHealth | <b>Origination Date:</b><br>11/30/2023 | <b>Effective Date:</b><br>03/24/2026  |
|  |   |  | <b>Last Review Date:</b><br>03/24/2026 | <b>Frequently Revision:</b><br>Annual |

### Policy History:

| Type of Review   | Summary of Changes  | P&T Approval Date | UM/CMPC Approval Date |
|------------------|---|-------------------|-----------------------|
| Annual Review    | Updated the policy to incorporate newly approved and guideline-supported daratumumab regimens, including the new Darzalex Faspro + VRd indication for newly diagnosed multiple myeloma in ASCT-ineligible patients, and aligned the dosing tables to current labeled schedules. Add new NCCN recommendation for use with venetoclax for t(11;14) systemic light chain amyloidosis; Update NCCN recommendation for relapsed/refractory multiple myeloma as a single agent after three lines of therapy including a PI and immunomodulatory agent. Added Darzalex Faspro dosing rows for high-risk smoldering multiple myeloma and updated AL amyloidosis dosing. Coding reviewed: expanded ICD10: E85.0-E85.9; added ICD10 D47.2. Updated reference list. Administrative update to incorporate new template. | 3/17/2026         | 03/24/2026            |
| Annual Review    | Add new indication as per FDA label for high-risk smoldering multiple myeloma as monotherapy.   | 12/3/2025         | 12/11/2025            |
| Annual Review    | Add combination use with venetoclax for consistency. Add regimen included in label information update (bortezomib, lenalidomide and dexamethasone).   | 6/9/2025          |                       |
| Select Review    | Add NCCN recommendations for combination use with selinexor and maintenance therapy in multiple myeloma; add pediatric acute lymphoblastic leukemia per NCCN. Coding Reviewed: Added ICD-10-CM C91.00-C91.02.   | 7/29/2024         | 8/7/2024              |
| Select Review    | Update statement for criteria for initial approval: Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient's diagnosis for the drug and confirming that the patient has met all approval criteria.   | 3/25/2024         | 5/9/2024              |
| Policy Inception | Elevance Health's Medical Policy adoption   | N/A               | 11/30/2023            |